Elite Pharmaceuticals Inc (ELTP) stock
ELTPOTCPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/30
$0.25−0.00 (-1.37%)
Close on Oct 19, 2026Market cap $283.02MP/E 5.0Yield –
Elite Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Elite Pharmaceuticals's cash was $38.94M at Jun 30, 2026. For fiscal 2026 it was $29.80M, up 163.3% from the year before. Over ten years it grew 10.0% a year on average. The highest annual figure on record is $29.80M in fiscal 2026.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $29.80M | +163.3% |
| FY2025 | Mar 31, 2025 | $11.32M | +59.2% |
| FY2024 | Mar 31, 2024 | $7.11M | -9.3% |
| FY2023 | Mar 31, 2023 | $7.83M | -8.2% |
| FY2022 | Mar 31, 2022 | $8.54M | +167.3% |
| FY2021 | Mar 31, 2021 | $3.19M | +107.8% |
| FY2020 | Mar 31, 2020 | $1.54M | -42.6% |
| FY2019 | Mar 31, 2019 | $2.68M | -64.7% |
| FY2018 | Mar 31, 2018 | $7.57M | -31.1% |
| FY2017 | Mar 31, 2017 | $10.98M | -4.6% |
| FY2016 | Mar 31, 2016 | $11.51M | +54.2% |
| FY2015 | Mar 31, 2015 | $7.46M | +7.5% |
| FY2014 | Mar 31, 2014 | $6.94M | +1781.1% |
| FY2013 | Mar 31, 2013 | $369.02K | -44.8% |
| FY2012 | Mar 31, 2012 | $668.41K | -63.4% |
| FY2011 | Mar 31, 2011 | $1.83M | +215.8% |
| FY2010 | Mar 31, 2010 | $578.19K | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $38.94M | +79.1% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $29.80M | +163.3% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $21.09M | +154.4% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $26.62M | +178.6% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $21.74M | +158.6% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $11.32M | +59.2% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $8.29M | +42.6% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $9.55M | +10.4% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $8.41M | -7.4% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $7.11M | -9.3% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $5.82M | -67.5% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $8.65M | -53.4% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $9.08M | -54.1% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $7.83M | -8.2% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $17.91M | +145.7% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $18.56M | +313.2% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $19.78M | +316.3% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $8.54M | +167.3% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $7.29M | +34.7% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $4.49M | -5.9% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $4.75M | +48.8% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $3.19M | +107.8% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $5.41M | +138.1% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $4.77M | +79.5% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $3.19M | +7.3% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $1.54M | -42.6% |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $2.27M | -44.2% |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | $2.66M | -47.9% |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $2.98M | -50.7% |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | $2.68M | -64.7% |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | $4.08M | -46.6% |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | $5.10M | -35.8% |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | $6.04M | -39.4% |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | $7.57M | -31.1% |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | $7.64M | -42.5% |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | $7.95M | -36.8% |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | $9.96M | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | $10.98M | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | $13.28M | – |
| Q2 FY2017CQ3 2016 | Sep 30, 2016 | $12.58M | – |
See a number that looks wrong?